La Jolla Pharmaceutical Co (LJPC) Market Valuation Rose While Broadfin Capital LLC Has Increased Stake

July 16, 2018 - By Megan Stone

La Jolla Pharmaceutical Company (NASDAQ:LJPC) LogoInvestors sentiment increased to 1.48 in Q1 2018. Its up 0.48, from 1 in 2017Q4. It is positive, as 12 investors sold LJPC shares while 21 reduced holdings. 22 funds opened positions while 27 raised stakes. 28.04 million shares or 15.19% more from 24.34 million shares in 2017Q4 were reported. Prudential Finance holds 0.01% in La Jolla Pharmaceutical Company (NASDAQ:LJPC) or 203,089 shares. Fmr Ltd Company accumulated 0.01% or 3.60M shares. Baker Bros Advsrs Limited Partnership reported 154,675 shares or 0.04% of all its holdings. Jpmorgan Chase And holds 137,144 shares. Bnp Paribas Arbitrage Sa owns 3,674 shares for 0% of their portfolio. Broadfin Capital Ltd Liability holds 1.66M shares. Moreover, State Street has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 1.48 million shares. J Goldman And Communications Limited Partnership has invested 0.07% of its portfolio in La Jolla Pharmaceutical Company (NASDAQ:LJPC). Perceptive Advisors Limited Liability Company invested in 4.31M shares or 3.6% of the stock. Ny State Common Retirement Fund has 20,700 shares for 0% of their portfolio. 2,117 are held by Zurcher Kantonalbank (Zurich Cantonalbank). Geode Capital Management Ltd holds 0% in La Jolla Pharmaceutical Company (NASDAQ:LJPC) or 170,842 shares. Alliancebernstein Limited Partnership, a New York-based fund reported 112,100 shares. Raymond James Assocs has 0% invested in La Jolla Pharmaceutical Company (NASDAQ:LJPC) for 8,743 shares. Rock Springs Cap Lp holds 0.28% in La Jolla Pharmaceutical Company (NASDAQ:LJPC) or 220,000 shares.

Since February 13, 2018, it had 6 insider purchases, and 0 sales for $44.23 million activity. Another trade for 175,000 shares valued at $5.73 million was made by PERCEPTIVE ADVISORS LLC on Tuesday, February 13. 508,474 La Jolla Pharmaceutical Company (NASDAQ:LJPC) shares with value of $15.00M were bought by TANG KEVIN C.

Kevin Kotler increased its stake in La Jolla Pharmaceutical Co (LJPC) by 60.87% based on its latest 2018Q1 regulatory filing with the SEC. Broadfin Capital Llc bought 626,854 shares as the company’s stock rose 1.17% while stock markets declined. The hedge fund run by Kevin Kotler held 1.66M shares of the biological products (no diagnostic substances) company at the end of 2018Q1, valued at $49.34M, up from 1.03 million at the end of the previous reported quarter. Broadfin Capital Llc who had been investing in La Jolla Pharmaceutical Co for a number of months, seems to be bullish on the $784.63M market cap company. The stock decreased 1.61% or $0.49 during the last trading session, reaching $30. About 147,103 shares traded. La Jolla Pharmaceutical Company (NASDAQ:LJPC) has risen 9.85% since July 16, 2017 and is uptrending. It has underperformed by 2.72% the S&P500.

Broadfin Capital Llc, which manages about $1.26 billion and $641.74M US Long portfolio, decreased its stake in Iovance Biotherapeutics Inc by 1.43M shares to 912,987 shares, valued at $15.43 million in 2018Q1, according to the filing. It also reduced its holding in Mirati Therapeutics Inc (NASDAQ:MRTX) by 1.00M shares in the quarter, leaving it with 1.44 million shares, and cut its stake in Angiodynamics Inc (NASDAQ:ANGO).

More news for La Jolla Pharmaceutical Company (NASDAQ:LJPC) were recently published by: Nasdaq.com, which released: “La Jolla Pharmaceutical Company Announces European Medicines Agency Validation of Marketing Authorisation …” on June 25, 2018. Seekingalpha.com‘s article titled: “Galectin Therapeutics IPF Patent Solidifies Platform Technology Status” and published on July 05, 2018 is yet another important article.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Ratings Coverage

Among 3 analysts covering La Jolla Pharma (NASDAQ:LJPC), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. La Jolla Pharma had 4 analyst reports since January 30, 2018 according to SRatingsIntel. The firm has “Underperform” rating by Jefferies given on Monday, February 12. The company was maintained on Friday, March 23 by Jefferies. Cowen & Co maintained the stock with “Buy” rating in Friday, May 11 report. The company was maintained on Tuesday, January 30 by H.C. Wainwright.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.